#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA3578684	B	Activation of recombinant human pancreatic glucokinase using 10 mM glucose as substrate by G6PDH coupled assay	Homo sapiens	24	ALA3576833	single protein format	Scientific Literature
2.	ALA3578770	B	Activation of recombinant human pancreatic glucokinase using 10 mM glucose as substrate assessed as enzyme half maximal saturation concentration at 1 uM by G6PDH coupled assay	Homo sapiens	24	ALA3576833	single protein format	Scientific Literature
3.	ALA3578771	B	Activation of glucokinase in rat primary hepatocytes assessed as increase in 5.6 mM 2-deoxy-D-[3H]-glucose uptake after 4 hrs by scintillation counting analysis relative to control	Rattus norvegicus	24	ALA3576833	cell-based format	Scientific Literature
4.	ALA3578772	B	Activation of recombinant human pancreatic glucokinase using 10 mM glucose as substrate assessed as enzyme Vmax by G6PDH coupled assay	Homo sapiens	1	ALA3576833	single protein format	Scientific Literature
5.	ALA3578773	B	Effect on hexokinase-1 (unknown origin)	Homo sapiens	1	ALA3576833	single protein format	Scientific Literature
6.	ALA3578774	B	Effect on hexokinase-2 (unknown origin)	Homo sapiens	1	ALA3576833	single protein format	Scientific Literature
7.	ALA3578775	B	Activation of glucokinase in 0 to 5.6 mM glucose-stimulated Sprague-Dawley rat pancreatic islets assessed as increase in insulin secretion after 1 hr by ELISA relative to control	Rattus norvegicus	1	ALA3576833	single protein format	Scientific Literature
8.	ALA3578776	F	Antidiabetic activity in C57BL/6 mouse assessed as reduction of blood glucose AUC at 50 mg/kg, po administered 30 mins prior to glucose challenge measured over 180 mins by OGTT relative to vehicle-treated control	Mus musculus	9	ALA3576833	organism-based format	Scientific Literature
9.	ALA3578777	F	Antidiabetic activity in C57BL/6 mouse assessed as reduction of blood glucose AUC at 30 mg/kg, po administered 30 mins prior to glucose challenge measured over 180 mins by OGTT relative to vehicle-treated control	Mus musculus	5	ALA3576833	organism-based format	Scientific Literature
10.	ALA3578778	F	Antidiabetic activity in po dosed C57BL/6J mouse assessed as blood glucose lowering effect administered 30 mins prior to glucose challenge measured over 180 mins by OGTT	Mus musculus	1	ALA3576833	organism-based format	Scientific Literature
11.	ALA3578779	F	Antidiabetic activity in C57BL/6J mouse assessed as blood glucose level at 30 mg/kg, po after 60 mins by fasted glucose tolerance test	Mus musculus	1	ALA3576833	organism-based format	Scientific Literature
12.	ALA3578780	T	Toxicity in C57BL/6J mouse assessed as hypoglycemic effect at 30 mg/kg, po after 60 mins	Mus musculus	1	ALA3576833	organism-based format	Scientific Literature
13.	ALA3578782	A	Clearance in ICR mouse at 3 mg/kg, iv and 10 mg/kg, po	Mus musculus	1	ALA3576833	organism-based format	Scientific Literature
14.	ALA3578783	A	Volume of distribution at steady state in ICR mouse at 3 mg/kg, iv and 10 mg/kg, po	Mus musculus	1	ALA3576833	organism-based format	Scientific Literature
15.	ALA3578784	A	Elimination half life in ICR mouse at 3 mg/kg, iv and 10 mg/kg, po	Mus musculus	1	ALA3576833	organism-based format	Scientific Literature
16.	ALA3578785	A	Oral bioavailability in ICR mouse at 10 mg/kg	Mus musculus	1	ALA3576833	organism-based format	Scientific Literature
17.	ALA3578786	P	Solubility of the compound at pH 7.4		1	ALA3576833	small-molecule physicochemical format	Scientific Literature
18.	ALA3578787	P	Apparent permeability of the compound by PAMPA		1	ALA3576833	small-molecule physicochemical format	Scientific Literature